Patient Case #1: Treatment Selection in mCNPC
Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.
Polling Questions: Advanced Prostate Cancer
Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.
Testing for the EGFR Exon 20 Insertion
Zofia Piotrowska, MD, shares insight on testing strategies for EGFR Exon 20 insertions, and which patients should be tested for these alterations.
Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions
Zofia Piotrowska, MD, provides an overview of EGFR mutations in advanced NSCLC, including EGFR Exon 20 insertions, and their clinical significance in patients with advanced NSCLC.
Improving the Management of HNSCC: Next Steps
Dr Cesar Perez reacts to the utilization of next-generation sequencing in head and neck squamous cell carcinoma and highlights future areas of study.
Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC
Recommendations for how to best treat patients with EGFR-mutated non–small cell lung cancer when there are discrepancies between clinical trial data and real-world evidence.
Treating Recurrent HER2+ Metastatic Breast Cancer Given Recent Clinical Trials
A panel of experts reviews clinical trial data in recurrent HER2-positive metastatic breast cancer and discusses impacts on treatment selection.
Treatment Landscape for HER2+ Metastatic Breast Cancer
Panelists provide an overview of the treatment landscape for patients with HER2-positive metastatic breast cancer.
Treatment Planning and Myelofibrosis
Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis
Risk Stratifying Patients With Myelofibrosis
Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.
Hossein Borghaei, DO, MS, Expresses Interest in DESTINY-Lung-1 Trial of Trastuzumab Deruxtecan in NSCLC
CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about the findings of the DESTINY-Lung01 study that were presented at 2021 ESMO.
Proactive Approaches to Preventing and Managing Chronic GVHD
Resources that can help educate patients and community physicians about the risk for chronic graft-vs-host disease post-transplantation.
Clinical Burden of Chronic GVHD
Risk factors associated with chronic graft-vs-host disease, and insight regarding how the condition commonly presents in patients.
Treatment Options for Steroid-Refractory Acute GVHD
Clinicians discuss how they treat patients with steroid-refractory acute graft-vs-host disease and consider where ruxolitinib fits into the therapeutic landscape.
Case 1: Treating a Patient With Acute GVHD
A panel of clinicians review the case of a patient with acute graft-vs-host disease and share how they typically approach similar scenarios.
HNSCC: Integrating Tipifarnib Into Treatment Algorithms
Potential implications of ongoing studies evaluating tipifarnib for patients with HRAS-mutated head and neck squamous cell carcinoma.
Next Steps in Using ctDNA as a Biomarker in CRC
Drs Liliana Bustamante and Richard Kim react to limitations surrounding biomarkers used in colorectal cancer and consider how to best study the role of ctDNA moving forward.
The Role of PARP Inhibitors and Adverse Events in Metastatic Prostate Cancer Therapy
An expert explains PARP inhibitor use in the metastatic prostate cancer treatment landscape and typical adverse events seen during therapies.
Selecting Appropriate Treatment and Monitoring Patients on Metastatic Prostate Cancer Therapy
Alicia Morgans, MD, MPH, discusses how to select the best treatment for patients with metastatic prostate cancer and the importance of monitoring them while on therapy.
Symptom Assessments in Myelofibrosis
The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.